This antibody SI-B001 is a significant development in hematologic treatment of relapsed multiple myeloma. This innovative antibody selectively interacts with BCMA of myeloma cells, inducing immune-mediated cellular cytotoxicity while promoting anti-tumor immune reactions. Initial